Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race but chose instead to back a runner from China's Hansh Pharma.
